CisplatinThird Party Manufacturing in India

Cisplatin is a first-generation platinum-based chemotherapy drug that works by directly damaging DNA in cancer cells. After entering the cell through passive diffusion and active transport via copper transporter CTR1, cisplatin undergoes aquation in the low-chloride intracellular environment. This process replaces its chloride ligands with water molecules, creating a highly reactive positively charged species. This activated cisplatin then binds preferentially to the N7 position of guanine bases in DNA, forming primarily intrastrand cross-links between adjacent guanine residues (1,2-d(GpG) adducts) which account for approximately 90% of all adducts. The remaining adducts include intrastrand ApG cross-links and interstrand cross-links. These covalent cross-links distort the DNA double helix, causing significant bending and unwinding that blocks DNA replication and transcription. The resulting DNA damage activates the ATM/ATR-mediated DNA damage response, leading to G2/M cell cycle arrest. If the damage is irreparable, the cell undergoes apoptosis through both the intrinsic mitochondrial pathway and the extrinsic death receptor pathway.

Therapeutic Uses

Cisplatin is prescribed for the treatment of:

• Testicular Cancer: Highly effective with cure rates exceeding 90% when used in combination regimens such as BEP (bleomycin, etoposide, cisplatin)
• Ovarian Cancer: First-line treatment for advanced ovarian cancer in combination with paclitaxel or other agents
• Bladder Cancer: Treatment of advanced or metastatic transitional cell carcinoma of the bladder
• Head and Neck Cancers: Used in concurrent chemoradiation for locally advanced squamous cell carcinoma
• Non-Small Cell Lung Cancer: Platinum-based doublet therapy is standard first-line treatment
• Cervical Cancer: Concurrent chemoradiation with cisplatin improves survival in locally advanced disease
• Mesothelioma: In combination with pemetrexed for unresectable malignant pleural mesothelioma
• Osteosarcoma: Part of multi-agent chemotherapy protocols for bone cancer

Why Manufacturers Choose Cisplatin

Cisplatin remains one of the most essential oncology drugs in the Indian pharmaceutical manufacturing landscape. It is listed on the WHO Essential Medicines List and is a cornerstone of numerous chemotherapy protocols across public health systems worldwide. Indian manufacturers produce cisplatin in multiple strengths, supplying both the domestic market where cancer incidence is rising and high-volume export markets including the US, Europe, Africa, and Southeast Asia. The drug's well-established safety profile, decades of clinical use, and predictable demand from cancer treatment centers make it a reliable product for contract manufacturing operations. Multiple strengths and its use in both standalone and combination therapy create diverse product line opportunities.

This makes Cisplatin one of the most sought-after molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.